Angelini Ventures co-leads €20 million Series A financing in Neumirna Therapeutics to Develop Next-Generation RNA Therapeutics for Epilepsy and…


Rome, Italy, 8 January 2025 – Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions and ideas in BioTech and Digital Health, today announces that it has co-led a €20 million Series A financing round in Neumirna Therapeutics, an RNA-focused biotech company developing next-generation therapeutics for neurological disorders.

The rest is here:
Angelini Ventures co-leads €20 million Series A financing in Neumirna Therapeutics to Develop Next-Generation RNA Therapeutics for Epilepsy and...

Related Posts